Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF 61 5-Year Yield-on-Cost % is 3.28 as of Jul. 26, 2026, which is 131% above its 10-year median of 1.42. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.68 (Fairly Valued). The stock has 4 warning signs investors should review. Among 150 Biotechnology companies, Sino Biopharmaceutical ranks better than 66% on this metric.
Sino Biopharmaceutical's yield on cost for the quarter that ended in Dec. 2025 was 3.28.
The historical rank and industry rank for Sino Biopharmaceutical's 5-Year Yield-on-Cost % or its related term are showing as below:
SBMFF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.6 Med: 1.42 Max: 5.93
Current: 3.28
During the past 13 years, Sino Biopharmaceutical's highest Yield on Cost was 5.93. The lowest was 0.60. And the median was 1.42.
SBMFF's 5-Year Yield-on-Cost % is ranked better than 66% of 150
companies
in the Biotechnology industry
Industry Median: 1.695
vs SBMFF: 3.28
Sino Biopharmaceutical (OTCPK:SBMFF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sino Biopharmaceutical 5-Year Yield-on-Cost % Related Terms
SBMFF vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's 5-Year Yield-on-Cost % falls into.
Sino Biopharmaceutical 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sino Biopharmaceutical (SBMFF) has a 5-Year Yield-on-Cost % of 3.28 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sino Biopharmaceutical and its competitors. This is 131% above median its historical median of 1.42. Over the past decade, Sino Biopharmaceutical's 5-Year Yield-on-Cost % has ranged from 0.60 to 5.93. According to the industry distribution chart, Sino Biopharmaceutical ranks #51 out of 150 companies in the Biotechnology industry, placing it in the top 34%.
Is Sino Biopharmaceutical's 5-Year Yield-on-Cost % too high?
Sino Biopharmaceutical's current 5-Year Yield-on-Cost % of 3.28 is 131% above median its 10-year median of 1.42. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 5.93. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. Sino Biopharmaceutical's value of 3.28 is 93.5% above this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #51 out of 150 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #51 out of 150 companies for 5-Year Yield-on-Cost %. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. Sino Biopharmaceutical's value of 3.28 is 93.5% above this benchmark. Historically, Sino Biopharmaceutical's own 5-Year Yield-on-Cost % has ranged from 0.60 to 5.93 over the past decade. While the company's 10-year median is 1.42 vs. the industry median of 1.70, Sino Biopharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current 5-Year Yield-on-Cost % of 3.28 is 93.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current 5-Year Yield-on-Cost % is 3.28, which is 131% above median its own 10-year median of 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.68, compared to a current price of $0.64 — trading 6.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.28, which is 131% above median its 10-year median of 1.42 and 93.5% above the Biotechnology industry median of 1.70. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current 5-Year Yield-on-Cost % is 3.28 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.64 is trading 6.3% below its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
5-Year Yield-on-Cost %: 3.28 (131% above median its 10-year median of 1.42)
GF Value™: $0.68 vs. price of $0.64 (6.3% below fair value)
Industry Position: 93.5% above the Biotechnology median (#51 of 150)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
